Cell lines:
- ZO-1 was found in BT483, MDA-MB-175, MCF-7, ZR-75-B, T-47D, SK-BR-3, CAMA-1, and MDA-MB-436 breast cancer cell (BCC) lines, but not in BT474, BT549, MDA-MB-134, -231, -361, -435, -453, -468, Hs578T, and MCF-7/Adr (doxorubicin-resistant) BCC lines (Sommers C.L. et al., 1994).
Tumors:
- The expression and subcellular localization of ZO-1 and
E-cadherin were investigated in paraffin-embedded breast cancer samples, using immunohistochemistry and confocal microscopy. While normal tissue showed intense staining for ZO-1 at the position of the epithelial tight junctions, this staining was reduced or lost in 69% of breast cancers analyzed (n = 48). ZO-1 staining was positively correlated with tumor differentiation (P = .011) and more specifically with the glandular differentiation of tumors (P = .0019). Reduction in ZO-1 staining was strongly correlated with reduced
E-cadherin staining (P = 4.9 x 10
-5). The results suggest that down-regulation of ZO-1 expression and its failure to accumulate at cell junctions may be causally related to cancer progression. To detect loss of heterozygosity, the ZO-1 gene was mapped relative to other markers in 15q13 and polymorphic markers flanking the gene were identified. The marker D15S1019 showed loss of heterozygosity in 23% of informative tumors (n = 13). This suggests that genetic loss may, in some cases, be responsible for the reduction in ZO-1 expression in breast cancer (Hoover K.B. et al., 1998).